People who have experienced a diagnosis of chronic hives may have a significantly higher risk of getting diagnosed with ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

It can take time to work. Some people treat their hives for 4 to 6 months before they see their skin clear. While it can be an effective treatment for many people, omalizumab doesn’t work for everyone ...

In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. Advertisement ALY-301 is the first mast cell-selective c-Kit ...

Alys Pharmaceuticals Announces CTA Submission For ALY-301, The First Mast Cell Selective C-Kit Inhibitor For Treatment Of Cold Urticaria Date 2025-06-10 03:45:59 ...

Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to ...

Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to initiate a ...

In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. ALY-301 is the first mast cell-selective c-Kit inhibitor to ...

Alys Pharmaceuticals Inc. has submitted a clinical trial application (CTA) to Germany’s Paul-Ehrlich-Institut (PEI) to initiate a phase I/Ib study of ALY-301 in healthy volunteers and patients with ...